版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
企業(yè)行業(yè)分析方案商業(yè)業(yè)態(tài)分類及特點(diǎn)商業(yè)業(yè)態(tài)包括百貨店、超級市場、大型綜合超市、便利店、專業(yè)市場（主題商城）、專賣店、購物中心和倉儲式商場等8
種形式。各主要業(yè)態(tài)選址和經(jīng)營特征如下。1、百貨店百貨店是指在一個大建筑物內(nèi)，根據(jù)不同商品部門設(shè)銷售區(qū)，開展進(jìn)貨、管理、運(yùn)營，滿足顧客對時尚商品多樣化選擇需求的零售業(yè)態(tài)。（1）選址在城市繁華區(qū)、交通要道。（2）商店規(guī)模大，營業(yè)面積在5000
平方米以上。（3）商品結(jié)構(gòu)以經(jīng)營男裝、女裝、兒童服裝、服飾、衣料、家庭用品為主，種類齊全、少批量、高毛利。（4）商店設(shè)施豪華、店堂典雅、明快。（5）采取柜臺銷售與自選（開架）銷售相結(jié)合方式。（6）采取定價銷售，可以退貨。（7）服務(wù)功能齊全。2、超級市場超級市場指采取自選銷售方式、以銷售食品、生鮮食品、副食品和生活用品為主，滿足顧客每日生活需求的零售業(yè)態(tài)。（1）址在居民區(qū)、交通要道、商業(yè)區(qū)。（2）以居民為主要銷售對象，10
分鐘左右可到達(dá)。（3）商店?duì)I業(yè)面積在1000
平方米左右。（4）商品構(gòu)成以購買頻率高的商品為主。（5）采取自選銷售方式，出入口分設(shè)，結(jié)算由設(shè)在出口處的收銀機(jī)統(tǒng)一進(jìn)行。（6）營業(yè)時間每天不低于11
小時。（7）有一定面積的停車場地。3、大型綜合超市大型綜合超市是指采取自選銷售方式，以銷售大眾化實(shí)用品為主，滿足顧客一次性購足需求的零售業(yè)態(tài)。（1）選址在城鄉(xiāng)結(jié)合部、住宅區(qū)、交通要道。（2）商店?duì)I業(yè)面積2500
平方米以上。（3）商品構(gòu)成為衣、食、用品齊全，重視本企業(yè)的品牌開發(fā)。（4）采取自選銷售方式。（5）設(shè)與商店?duì)I業(yè)面積相適應(yīng)的停車場。4、便利店（方便店）便利店是滿足顧客便利性需求為主要的目的的零售業(yè)態(tài)。（1）選址在居民住宅區(qū)、主干線公路邊，以及車站、醫(yī)院、娛樂場所、機(jī)關(guān)、團(tuán)體、企業(yè)事業(yè)所在地。（2）商店?duì)I業(yè)面積在100
平方米左右，營業(yè)面積利用率高。（3）居民徒步購物5-7
分鐘可到達(dá)，80%的顧客為有目的的購買。（4）商品結(jié)構(gòu)以速成食品、飲料、小百貨為主，有即時消費(fèi)性、小容量、應(yīng)急商業(yè)業(yè)態(tài)分類及特點(diǎn)性等特點(diǎn)。（5）營業(yè)時間長，一般在10
小時以上，甚至24
小時，終年無休日。（6）以開架自選貨為主，結(jié)算在收銀機(jī)處統(tǒng)一進(jìn)行。5、購物中心購物中心指企業(yè)有計(jì)劃地開發(fā)、擁有、管理運(yùn)營的各類零售業(yè)態(tài)、服務(wù)設(shè)施的集合體。（1）由發(fā)起者有計(jì)劃地開設(shè)、布局統(tǒng)一規(guī)劃，店鋪獨(dú)立經(jīng)營。（2）選址為中心商業(yè)區(qū)或城鄉(xiāng)結(jié)合部的交通要道。（3）內(nèi)部結(jié)構(gòu)由百貨店或超級市場作為核心店，與各類專業(yè)店、專賣店、快餐店等組合構(gòu)成。（4）設(shè)施豪華、店堂典雅、寬敞明亮，實(shí)行賣場租賃制。（5）核心店的面積一般不超過購物中心面積的80%。（6）服務(wù)功能齊全，集零售、餐飲、娛樂為一體。（7）根據(jù)銷售面積，設(shè)相應(yīng)規(guī)模的停車場。6、倉儲式商場倉儲式商場指以經(jīng)營生活資料為主的，儲銷一體、低價銷售、提供有限服務(wù)的零售業(yè)態(tài)（其中有的采取會員制形式，只為會員服務(wù)）。（1）在城鄉(xiāng)結(jié)合部、交通要道。（2）商店?duì)I業(yè)面積大，一般為10000
平方米左右。（3）目標(biāo)顧客以中小零售商、餐飲店、集團(tuán)購買和有交通工具的消費(fèi)者為主。（4）商品結(jié)構(gòu)主要以食品（有一部分生鮮商品）、家庭用品、體育用品、服裝衣料、文具、家用電器、汽車用品、室內(nèi)用品等為主。（5）店堂設(shè)施簡樸、實(shí)用。（6）采取倉儲式陳列。（7）開展自選式的銷售。（8）設(shè)有較大規(guī)模的停車場。商業(yè)業(yè)態(tài)分類及特點(diǎn)行業(yè)文檔手冊Report
Code:Published:GDHC1299EIJune
2017
商業(yè)分析研究報告文檔
GlobalData干細(xì)胞生命醫(yī)學(xué)應(yīng)用臨床報告英文
2017623Global
Trends
in
Stem
Cell
TherapyClinical
TrialsA
10-Year
Retrospective,
2007–2016Healthcare
分析報告文檔行業(yè)文檔手冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare11
Table
of
ContentsTable
of
Contents........................................................................................................................................................
21.1List
of
Figures
...................................................................................................................................................................32Introduction................................................................................................................................................................
42.12.22.3Report
Scope....................................................................................................................................................................4Methodology....................................................................................................................................................................4Organizations
Mentioned.................................................................................................................................................43Stem
Cell
Therapy
Trial
Landscape...............................................................................................................................
53.13.23.33.43.53.63.73.83.9Introduction
.....................................................................................................................................................................5Stem
Cell
Therapy
Clinical
Trials
by
Phase
and
Sponsor
Type,
2007–2016......................................................................5Single-Country
and
Multinational
Stem
Cell
Therapy
Trials,
2007–2016.........................................................................8Average
Size
of
Stem
Cell
Therapy
Clinical
Trials,
2007–2016.........................................................................................9Stem
Cell
Therapy
Clinical
Trials
by
Therapy
Area,
2007–2016
.....................................................................................11Top
Indications
for
Stem
Cell
Therapy
Clinical
Trials,
2007–2016..................................................................................12Stem
Cell
Therapy
Clinical
Trials
by
Status,
2007–2016.................................................................................................14Top
Sponsors
for
Stem
Cell
Therapy
Clinical
Trials,
2007–2016
....................................................................................15Top
Interventions
Investigated
in
Stem
Cell
Therapy
Clinical
Trials,
2007–2016...........................................................173.10
Stem
Cell
Therapy
Clinical
Trials
by
Country,
2007–2016..............................................................................................1845Summary
..................................................................................................................................................................
19About
the
Authors
....................................................................................................................................................
205.15.2Associate
Analyst,
Clinical
Trials
Database.....................................................................................................................20Global
Director
of
Databases
and
Analytics...................................................................................................................2067About
the
Pharmaceutical
Clinical
Trials
Team...........................................................................................................
21About
GlobalData......................................................................................................................................................
227.17.2Contact
Us......................................................................................................................................................................22Disclaimer.......................................................................................................................................................................23Published:
June
2017
商業(yè)分析研究報告文檔分析報告文檔
2行業(yè)文檔手冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare1.1List
of
FiguresPublished:
June
2017
商業(yè)分析研究報告文檔Figure
1:
Stem
Cell
Therapy
Clinical
Trials
by
Phase
,
2007–2016.....................................................................................................6Figure
2:
Stem
Cell
Therapy
Clinical
Trials
by
Sponsor
Type,
2007–2016
.........................................................................................7Figure
3:
Stem
Cell
Therapy
Single-Country
and
Multinational
Trials,
2007–2016...........................................................................8Figure
4:
Average
Size
of
Stem
Cell
Therapy
Clinical
Trials,
2007–2016
...........................................................................................9Figure
5:
Stem
Cell
Therapy
Clinical
Trials
by
Average
Number
of
Locations,
2007–2016
.............................................................10Figure
6:
Stem
Cell
Therapy
Clinical
Trials
by
Therapy
Area
and
Sponsor
Type,
2007-2016...........................................................11Figure
7:
Stem
Cell
Therapy
Clinical
Trials
for
the
Top
Five
Indications
by
Sponsor
Type,
2007–2016...........................................12Figure
8:
Stem
Cell
Therapy
Clinical
Trials
for
the
Top
Five
Indications
by
Phase,
2007–2016.......................................................13Figure
9:
Status
of
Stem
Cell
Therapy
Clinical
Trials
by
Sponsor
Type,
2007–2016........................................................................14Figure
10:
Top
Industry
Sponsors
for
Stem
Cell
Therapy
Clinical
Trials,
2007–2016
......................................................................15Figure
11:
Top
Non-Industry
Sponsors
for
Stem
Cell
Therapy
Clinical
Trials,
2007–2016
..............................................................16Figure
12:
Top
Drugs
Investigated
in
Stem
Cell
Therapy
Clinical
Trials,
2007–2016.......................................................................17Figure
13:
Stem
Cell
Therapy
Clinical
Trials
by
Country,
2007–2016..............................................................................................18
分析報告文檔
3商業(yè)市場調(diào)研報告是指調(diào)查和收集有關(guān)商業(yè)市場需求、消費(fèi)者行為、競爭狀況、市場趨勢等方面的信息，從而為企業(yè)決策者提供有助于確定市場方向和制定營銷策略的實(shí)用數(shù)據(jù)和建議。在當(dāng)今商業(yè)競爭日益激烈的環(huán)境下，商業(yè)市場調(diào)研報告對企業(yè)的發(fā)展至關(guān)重要。商業(yè)市場調(diào)研報告的形式和內(nèi)容可因行業(yè)和目標(biāo)而異，通常包括市場情況、產(chǎn)品特色、消費(fèi)者行為和需求、競爭對手及其策略等方面的信息。針對不同的信息，企業(yè)可以采用各種方式來獲取市場數(shù)據(jù)，如調(diào)查問卷、訪談、觀察等方式。在調(diào)研報告中，企業(yè)需要對市場數(shù)據(jù)和信息進(jìn)行分析，得出結(jié)論和建議，并據(jù)此提供具體的市場營銷策略和行動方案。此外，企業(yè)還應(yīng)該對己行動的效果及時追蹤和評估，并針對性地調(diào)整和完善市場策略。商業(yè)市場調(diào)研過程中，我們首先需要考慮的是需要確定的目標(biāo)。調(diào)研目標(biāo)應(yīng)據(jù)此制定市場調(diào)研方案。通常包括需求滿足度、市場規(guī)模、產(chǎn)品可行性和客戶類型等。調(diào)研計(jì)劃的其他方面包括調(diào)研方式、調(diào)研時期和成本等。商業(yè)調(diào)研分析報告作用行業(yè)文檔手冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare22.1IntroductionReport
ScopeThis
whitepaper
provides
a
review
of
global
clinical
trials
for
stem
cell
therapy
initiated
between
2007and
2016.
The
data
for
this
review
were
derived
from
the
Clinical
Trials
Database
of
GlobalData’sPharma
Intelligence
Center.
The
aim
of
this
paper
is
to
provide
analyses
of
the
main
features
of
thesetrials
according
to
10-year
trends,
where
relevant.2.2MethodologyThe
clinical
trials
data
used
for
these
analyses
were
extracted
from
the
Clinical
Trials
Database
ofGlobalData’s
Pharma
Intelligence
Center.
The
data
included
global
interventional
trials
(94.9%),observational
trials
(5.0%),
and
one
expanded
access
clinical
trial,
all
of
which
had
an
initiationbetween
January
1,
2007
and
December
31,
2016.
The
Clinical
Trials
Database
of
the
PharmaIntelligence
Center
recorded
584
trials
that
satisfied
the
above
criteria.
The
data
were
analyzed
andsegmented
by
sponsor
type,
trial
phases,
single
or
multinational
location,
size,
therapy
area,
topindications,
status,
leading
industry
drugs,
and
trial
locations
investigated
in
the
trials.
Furtheranalyses
were
carried
out
on
the
dataset
to
identify
the
top
sponsors,
and
the
top
Contract
ResearchOrganizations
(CROs)
involved.2.3Organizations
MentionedPublished:
June
2017
商業(yè)分析研究報告文檔The
companies
mentioned
in
this
whitepaper
include
Aderans
Research
Institute,
Anterogen,
Celgene,City
of
Hope,
Great
Ormond
Steet
Hospital,
MediPost,
Mesoblast,
Microbot
Medical,
NanfangHospital,
Neuralstem,
Pluristem
Therapeutics,
Samsung
Medical
Center,
Stempeutics
Research,TiGenix,
University
of
California
and
Los
Angeles,
Universiti
of
Kebangsaan
Malaysia,
University
ofMiami,
University
of
Texas,
and
US
Stem
Cell.
分析報告文檔
4行業(yè)文檔手冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare33.1Stem
Cell
Therapy
Trial
LandscapeIntroductionGlobalData
analyzed
the
number
of
trials
carried
out
by
industry
and
non-industry
sponsors
todetermine
the
top
sponsors
involved
in
these
clinical
trials,
as
well
as
the
top
investigational
drugs.Global
Data
also
looked
at
the
locations
that
hosted
the
most
clinical
trials,
and
studied
the
mostpopular
therapy
areas
and
the
characteristics
of
the
populations
involved
in
the
clinical
trials.GlobalData
identified
584
stem
cell
therapy
clinical
trials
with
a
start
date
between
2007
and
2016.The
total
number
of
stem
cell
therapy
trials
featured
a
steady
year-on-year
increase
from
2007
to2012,
from
31
to
70
clinical
trials
globally,
followed
by
a
small
decrease
to
67
in
2013.
There
was
thena
continuous
increase
until
2015,
which
saw
the
highest
number
of
stem
cell
therapy
trials
at
74globally.
The
10
year
period
ended
in
2016
with
69
trials.3.2Stem
Cell
Therapy
Clinical
Trials
by
Phase
and
Sponsor
Type,
2007–2016Stem
cell
therapy
trialsexperienced
theirhighest
growth
in2015,
with
74
trialsbeing
initiated
in
thatyear.Published:
June
2017
商業(yè)分析研究報告文檔In
this
report,
a
small
number
of
Phase
0,
Phase
I/II,
Phase
II/III,
and
Phase
III/IV
trials
were
combinedwith
Phase
I,
Phase
II,
Phase
III,
and
Phase
IV
trials,
respectively.
Overall,
there
was
a
predominance
ofPhase
I
and
Phase
II
trials
as
compared
to
Phase
III
and
Phase
IV
trials,
except
for
2007
when
Phase
IIItrials
took
second
place
instead
of
those
in
Phase
II.
The
yearly
contribution
of
Phase
I
stem
celltherapy
trials
saw
an
increase
from
16%
in
2007
to
35%
in
2009,
followed
by
a
decrease
to
17%
in2012,
as
shown
in
Figure
1.
The
following
five
years
saw
continuous
increases
in
contribution
of
PhaseI
trials
to
a
10-year
peak
of
38%
in
2016.
Phase
II
had
the
highest
contribution
in
2012
and
2013
at71%
and
75%,
respectively.
From
2013
onwards
there
was
a
year-on-year
decrease
until
2016,
whichhad
the
lowest
contribution
of
Phase
II
trials
at
48%.
Phase
III
trials
started
off
very
strong
at
a
peak
of32%
of
in
2007,
then
had
a
continual
decrease
and
hit
an
all-time
low
of
6%
in
2010.
From
this
yearonwards
there
were
fluctuations
between
7%
and
12%
until
2016.
The
contribution
of
Phase
IV
trialspresented
the
lowest
contribution
numbers
overall.
The
highest
contribution
of
Phase
IV
trials
was
3%in
2016;
between
2007
and
2010
there
was
no
trial
registered
at
Phase
IV.
分析報告文檔
5Number
of
Trials檔行業(yè)文手冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare2007200820092010201120122013201420152016PhaseIPhaseIIPhaseIIIPhaseIVPublished:
June
2017
商業(yè)分析研究報告文檔
Figure
1:
Stem
Cell
Therapy
Clinical
Trials
by
Phase
,
2007–2016
80
70
60
50
40
30
20
10
0Source:
GlobalData
Pharmaceutical
Intelligence
Center,
Clinical
Trials
Database
[Accessed
May
22,
2017]
分析報告文檔
6一、市場調(diào)研報告是企業(yè)了解市場動態(tài)的窗口。它有利于企業(yè)掌握市場動態(tài)，如市場供求情況、市場最新趨勢、消費(fèi)者的要求以及本企業(yè)產(chǎn)品的銷售情況等方面的市場動態(tài)。二、它為企業(yè)客觀判斷自身的競爭能力，調(diào)整經(jīng)營決策、產(chǎn)品開發(fā)和生產(chǎn)計(jì)劃提供了依據(jù)，企業(yè)在市場競爭中要想明確自身所處的位置，就要做市場調(diào)查，從市場調(diào)查報告中獲取準(zhǔn)確的信息。企業(yè)領(lǐng)導(dǎo)層在考慮開發(fā)新產(chǎn)品，決定產(chǎn)品的生產(chǎn)數(shù)量、品種、花色時也要先做市場調(diào)查。三、有助于整體宣傳策略需要，為企業(yè)市場地位和產(chǎn)品宣傳等提供信息和支持。四、通過市場調(diào)查所獲得的資料，除了可供了解目前市場的情況之外，還可以對市場變化趨勢進(jìn)行預(yù)測，從而可以提前對企業(yè)的應(yīng)變作出計(jì)劃和安排，充分地利用市場的變化，從中謀求企業(yè)的利益。商業(yè)調(diào)研分析報告作用Number
of
Trials行業(yè)文檔手冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare2007200820092010201120122013201420152016Industry
SponsorNon-Industry
SponsorPublished:
June
2017
商業(yè)分析研究報告文檔Over
this
period
and
across
all
stages
of
development,
there
were
more
trials
sponsored
by
industrysponsors
than
non-industry
sponsors.
Non-industry
sponsored
trials
saw
an
increase
from
13
to
29trials
from
2007
to
2012,
which
was
the
highest
amount
of
non-industry
trials
over
the
10-yearperiod.
Industry
trials
saw
an
increase
from
18
trials
in
2007
to
their
highest
level
at
53
trials
in
2014,as
shown
in
Figure
2.
Figure
2:
Stem
Cell
Therapy
Clinical
Trials
by
Sponsor
Type,
2007–2016
60
50
40
30
20
10
0Source:
GlobalData
Pharmaceutical
Intelligence
Center,
Clinical
Trials
Database
[Accessed
May
22,
2017]
分析報告文檔
7冊行業(yè)文檔手Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare3.3Single-Country
and
Multinational
Stem
Cell
Therapy
Trials,
2007–2016There
were,
on
average,
7.1
times
as
many
single-country
trials
as
multinational
trials
over
the
10-year
period.
As
shown
in
Figure
3,
the
total
number
of
multinational
trials
was
at
its
largest
in
2014
at12
trials,
and
was
at
an
all-time
low
in
2009
at
two
trials.
Single-country
trials
saw
an
increasebetween
2007
and
2012,
from
22
trials
to
61
trials,
their
highest
level
in
the
10-year
period.
Thebiggest
decrease
of
single-country
trials
was
seen
from
2015
to
2016,
where
it
fell
by
22%,
as
shownin
Figure
3.
Figure
3:
Stem
Cell
Therapy
Single-Country
and
Multinational
Trials,
2007–2016
70
60
50
40
30
20
10
02007200820092010201120122013201420152016SingleCountryMultinationalPublished:
June
2017
商業(yè)分析研究報告文檔Source:
GlobalData
Pharmaceutical
Intelligence
Center,
Clinical
Trials
Database
[Accessed
May
22,
2017]
分析報告文檔
8手行業(yè)文檔冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare3.4Average
Size
of
Stem
Cell
Therapy
Clinical
Trials,
2007–2016
The
average
size
of
clinical
trials
in
terms
of
number
of
subjects
planned
across
both
multinationaland
single-country
trials
saw
a
decrease
of
59%,
from
92
to
38
for
patient
subject
trials
between
2007and
2016.
In
contrast,
the
average
size
of
clinical
trials
involving
healthy
subjects
increased
by
429%,from
17
to
90
between
2007
and
2016.
The
largest
number
of
average
healthy
participants
was
seenin
2015.
This
was
primarily
due
to
a
multinational
trial
sponsored
by
Mesoblast
and
carried
out
withassistance
of
Quintiles.
However,
when
comparing
the
number
of
this
trial’s
participants
to
the
wholedataset,
its
deviation
from
the
mean
was
not
large
enough
to
justify
its
exclusion
from
the
dataset.One
very
large
clinical
trial
involving
patient
participants
was
removed
from
the
analysis
as
an
outlierfor
the
purposes
of
the
representation
shown
in
Figure
4.
Figure
4:
Average
Size
of
Stem
Cell
Therapy
Clinical
Trials,
2007–2016
140
120
100
80
60
40
20
02007200820092010201120122013201420152016AveragePatient
SubjectsAverageHealthy
SubjectsPublished:
June
2017
商業(yè)分析研究報告文檔Source:
GlobalData
Pharmaceutical
Intelligence
Center,
Clinical
Trials
Database
[Accessed
May
22,
2017]
分析報告文檔
9商品和服務(wù)是由生產(chǎn)者轉(zhuǎn)移到消費(fèi)者而形成市場行銷活動的鏈接方式，或投資者對自己確立的項(xiàng)日存有疑惑，而委請專業(yè)的調(diào)查人員或第三者，作有系統(tǒng)地、客觀地、廣泛地且持續(xù)地搜集相關(guān)資料，加以記錄，分析，衡量與評估，提供相關(guān)分析，結(jié)論與建議，以供企業(yè)經(jīng)營者決策參考之行為。市場調(diào)研范圍1·市場研究：市場潛在需求量，消費(fèi)者分布及消費(fèi)者特性研究。2.產(chǎn)品研究：產(chǎn)品設(shè)計(jì)，開發(fā)及試驗(yàn)；消費(fèi)者對產(chǎn)品形狀、包裝、品味等喜好研究；現(xiàn)有產(chǎn)品改良建議，競爭產(chǎn)品的比較分析。3,銷售研究：公司總體行銷活動研究，設(shè)計(jì)及改進(jìn)。4.消費(fèi)購買行為研究：消費(fèi)者購買動機(jī)，購買行為決策過程及購買行為特性研究。5.廣告及促銷研究：測驗(yàn)及評估商品廣告及其它各種促銷之效果，尋求最佳促銷手法，以促進(jìn)消費(fèi)者有效購買行為。6.行銷環(huán)境研究：依人口、經(jīng)濟(jì)、社會、政治及科技等因素變化及未來變化走勢，對市場結(jié)構(gòu)及企業(yè)行銷策略的影響。7.銷售預(yù)測：研究大環(huán)境演變，競爭情況及企業(yè)相對競爭優(yōu)勢，對于市場銷售量作長期與短期預(yù)測，為企業(yè)擬定長期經(jīng)營計(jì)劃及短期經(jīng)營計(jì)劃之用。商業(yè)調(diào)研分析報告作用行業(yè)文檔手冊Subjects/
Site
(N)Locations(N)Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare35302520151050765432102007200820092010201120122013201420152016AverageLocationsAverageSubjects
perSite
(Right)Published:
June
2017
商業(yè)分析研究報告文檔In
terms
of
average
number
of
locations
within
single-country
trials,
the
clinical
trials’
size
decreasedgradually
from
5.3
to
2.8
locations
overall
between
2007
and
2011.
In
2012,
the
average
number
oflocations
in
single
country
trial
hit
a
10-year
high
of
6.3;
this
was
largely
due
to
two
trials
at
Phase
IIIand
one
trial
at
Phase
II
stage
of
development
and
were
held
in
the
US.
The
lowest
amount
oflocations
in
single
country
trials
across
the
10-year
period
occurred
in
2016.
The
average
number
ofsubjects
planned
per
site
decreased
from
27
in
2007
to
18
in
2008.
The
number
of
planned
subjectsper
site
ranged
between
17
and
32
over
the
10-year
period,
with
its
peak
in
2013,
as
shown
in
Figure5.
Figure
5:
Stem
Cell
Therapy
Clinical
Trials
by
Average
Number
of
Locations,
2007–2016Source:
GlobalData
Pharmaceutical
Intelligence
Center,
Clinical
Trials
Database
[Accessed
May
22,
2017]
分析報告文檔
10行業(yè)文檔手冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare3.5Stem
Cell
Therapy
Clinical
Trials
by
Therapy
Area,
2007–2016050100150200According
to
therapy
area,
Oncology
had
the
largest
distribution
of
clinical
trials,
with
269
trials
fromboth
industry
and
non-industry
sponsors.
Cardiovascular
had
the
second
largest,
with
245
trials
forboth
sponsor
types,
followed
by
Central
Nervous
System
with
137
trials,
Musculoskeletal
Disorderswith
88
trials,
and
Immunology
with
87
trials,
as
shown
in
Figure
6.
The
Immunology
therapy
areafeatured
more
non-Industry
sponsored
trials
than
industry
sponsored
trials.
However,
within
theOncology,
Musculoskeletal
Disorders,
Cardiovascular,
and
Central
Nervous
System
areas,
there
weremore
industry
sponsored
trials
featured
than
non-industry
sponsored
trials.
Figure
6:
Stem
Cell
Therapy
Clinical
Trials
by
Therapy
Area
and
Sponsor
Type,
2007-2016
Oncology
Cardiovascular
CentralNervous
System
Musculoskeletal
Disorders
ImmunologyNon-Industry
SponsorsIndustry
SponsorsPublished:
June
2017
商業(yè)分析研究報告文檔Source:
GlobalData
Pharmaceutical
Intelligence
Center,
Clinical
Trials
Database
[Accessed
May
22,
2017]
分析報告文檔
11行業(yè)文檔手冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare3.6Top
Indications
for
Stem
Cell
Therapy
Clinical
Trials,
2007–20160510152025Among
the
indications
for
clinical
trials
in
this
dataset,
the
largest
number
of
trials
was
carried
out
forstem
cell
therapy
was
myocardial
infarction,
followed
by
graft
versus
host
disease,
congestive
heartfailure,
critical
limb
ischemia,
and
osteoarthritis,
as
seen
in
Figure
8.
For
all
indications
except
graftversus
host
disease,
industry
sponsors
were
more
prominent
than
non-industry
sponsors.
There
were11.5
times
as
many
industry
sponsored
trials
than
non-industry
sponsored
trials
for
osteoarthritis,which
was
the
highest
ratio
compared
to
all
other
indications,
as
shown
in
Figure
7.
In
graft
versushost
disease,
non-industry
and
industry
sponsored
trials
were
approximately
even.
Figure7:StemCellTherapyClinicalTrialsfortheTopFiveIndicationsbySponsorType,2007–2016
Myocardial
Infarction
Graft
Versus
Host
Disease
(GVHD)
CongestiveHeart
Failure
(Heart
Failure)
CriticalLimb
Ischemia
OsteoarthritisNon-Industry
SponsorIndustry
SponsorIndustry-sponsoredtrials
dominated
acrossfour
of
the
five
majorindications.Published:
June
2017
商業(yè)分析研究報告文檔Source:
GlobalData
Pharmaceutical
Intelligence
Center,
Clinical
Trials
Database
[Accessed
May
22,
2017]
分析報告文檔
12隨著各種問題的不斷出現(xiàn)，對策建議類調(diào)研報告成為了越來越重要的工具，可以幫助企業(yè)和組織制定有效的戰(zhàn)略和方案。本次調(diào)研共收集了31篇有關(guān)對策建議類調(diào)研報告，發(fā)現(xiàn)了一些有趣且關(guān)鍵的共性和差異。首先，從研究內(nèi)容來看，這些報告所關(guān)注的問題是非常多樣化的。其中有些報告關(guān)注的是社會問題和政策，如貧困和教育問題，而另外一些報告則更加關(guān)注企業(yè)和組織的內(nèi)部問題，如管理和市場營銷。這種多樣性并不能算是這些報告的缺陷，相反，它說明我們的社會和組織面臨的挑戰(zhàn)十分繁多，需要我們從各個方面入手才能夠解決問題。其次，這些報告在調(diào)查方法和數(shù)據(jù)分析方面也存在差異。大部分的報告采用了定性和定量結(jié)合的方式，通過問卷調(diào)查、實(shí)地考察和專家訪談等方式收集數(shù)據(jù)。然而，也有一些報告采用了更為創(chuàng)新的技術(shù)，如大數(shù)據(jù)分析和人工智能技術(shù)。這些新技術(shù)雖然還處于試驗(yàn)階段，但它們可能會以越來越多的方式成為調(diào)研方法的重要組成部分。最后，這些報告在對策和建議方面表現(xiàn)出了不同的風(fēng)格和實(shí)用性。有些報告提出了具有長遠(yuǎn)發(fā)展戰(zhàn)略的行動方案，而另外一些則更注重于針對特定問題提供現(xiàn)實(shí)可行的解決方案。這些不同的風(fēng)格反映了報告的作者們的不同經(jīng)驗(yàn)和專業(yè)背景，并吸引了各個方面的讀者。商業(yè)調(diào)研分析報告作用行業(yè)文檔手冊Global
Trends
in
Stem
Cell
Therapy
Clinical
Trials
–
A
10-Year
Retrospective,
2007–2016Reference
Code:
GDHC1299EIHealthcare05101520253035PhaseIPhaseIIPhaseIIIPhaseIVPublished:
June
2017
商業(yè)分析研究報告文檔For
the
five
major
indications,
Phase
II
trials
were
predominant;
critical
limb
ischemia
had
the
mosttrials
for
that
phase,
as
shown
in
Figure
溫馨提示
- 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間，僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請與我們聯(lián)系，我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025年小學(xué)班主任個人工作總結(jié)范文
- 出售鋼管配件合同范例
- 2024-2025學(xué)年河南省開封市高一上冊10月月考數(shù)學(xué)學(xué)情檢測試題
- 個人工資合同范例
- vip會員合同范例
- 農(nóng)業(yè)運(yùn)輸雇工合同范例
- Unit 5 Lesson 2 The rhino and the egret2024-2025學(xué)年新教材七年級英語上冊同步教學(xué)設(shè)計(jì)(冀教版2024)河北專版
- 供電產(chǎn)品購銷合同范例
- 衛(wèi)浴材料供貨合同范例
- 出租大箱貨車合同范例
- 2024年中考英語熱點(diǎn)閱讀練習(xí)-人工智能AI（含解析）
- 中國慢性便秘診治指南課件
- 2024年同等學(xué)力申碩-同等學(xué)力(經(jīng)濟(jì)學(xué))筆試考試歷年真題含答案
- Module 5 Unit 2 公開課教學(xué)設(shè)計(jì)（外研版九年級下冊教案）
- AQ-T 3002-2021阻隔防爆橇裝式加油（氣）裝置技術(shù)要求
- （正式版）QBT 8022-2024 冷凍飲品 食用冰
- 危大工程安全檢查錄表
- 北師大版心理健康四年級下冊全冊教案教學(xué)設(shè)計(jì)
- 品牌服裝設(shè)計(jì)課件
- 肝病科進(jìn)修總結(jié)匯報
- 化妝品企業(yè)質(zhì)量管理手冊
評論
0/150
提交評論